origin
research
c
opd
increas
health
problem
worldwid
exacerb
episod
acut
symptomat
physiolog
function
deterior
import
consequ
patient
healthcar
provid
predominantli
trigger
infect
exacerb
associ
cold
common
respiratori
viru
detect
airway
exacerb
human
rhinoviru
hrv
use
molecular
techniqu
identifi
ed
present
respiratori
virusassoci
exacerb
background
human
rhinoviru
hrv
frequent
viru
associ
copd
exacerb
viral
infect
increas
exacerb
sever
likelihood
hospit
eas
sampl
blood
make
serum
practic
marker
sputum
investig
whether
chang
serum
interferong
induc
protein
baselin
exacerb
higher
airway
hrvposit
exacerb
whether
level
relat
hrv
load
method
one
hundr
thirtysix
patient
copd
control
includ
year
exacerb
sampl
hrv
posit
load
determin
revers
transcriptasepolymeras
chain
reaction
nasopharyng
swab
andor
sputum
baselin
exacerb
measur
enzymelink
immunosorb
assay
serum
compar
hrv
load
copd
control
median
pgml
pgml
p
presenc
hrv
baselin
increas
patient
copd
pgml
pgml
p
control
pgml
pgml
p
increas
significantli
baselin
exacerb
hrvposit
exacerb
pgml
pgml
p
chang
baselin
exacerb
hrvneg
exacerb
pgml
pgml
p
exacerb
correl
sputum
viral
load
rho
p
receiv
oper
characterist
analysi
combin
coryz
symptom
gave
area
curv
ci
conclus
increas
baselin
exacerb
hrvposit
exacerb
correl
sputum
hrv
load
serum
may
use
novel
marker
event
abbrevi
auc
area
curv
crp
creactiv
protein
hrv
human
rhinoviru
il
interleukin
interferong
induc
protein
iqr
interquartil
rang
np
nasopharyng
swab
pcr
polymeras
chain
reaction
roc
receiv
oper
characterist
patient
copd
complet
daili
diari
card
record
increas
daili
respiratori
symptom
exacerb
defi
ned
accord
previous
valid
criteria
two
symptom
least
one
major
consecut
day
opinion
attend
clinician
patient
exacerb
major
symptom
increas
dyspnea
sputum
volum
sputum
purul
minor
symptom
increas
cough
wheez
sore
throat
coryz
symptom
exacerb
definit
valid
chang
qualiti
life
infl
ammatori
marker
fev
declin
exacerb
visit
inform
collect
symptom
type
durat
spirometri
perform
blood
taken
cytokin
assay
sputum
collect
spontan
produc
np
taken
exacerb
treat
bronchodil
antibiot
andor
oral
steroid
sampl
taken
prior
initi
treatment
one
exacerb
per
patient
analyz
fi
rst
report
sampl
exacerb
studi
period
venou
blood
ml
collect
centrifug
g
min
within
h
collect
serum
separ
store
later
analysi
serum
quantifi
ed
use
commerci
sandwich
enzymelink
immunosorb
assay
kit
r
system
abingdon
england
serum
crp
measur
hospit
laboratori
use
olympu
luminometr
analyz
limit
detect
serum
pgml
pgml
crp
mgl
sampl
process
upper
lower
airway
nasopharyng
swab
rotat
fi
six
time
allow
remain
cold
symptom
exacerb
increas
sever
exacerb
lengthen
recoveri
time
confi
rmed
polymeras
chain
reaction
pcr
exacerb
associ
higher
level
airway
infl
ammatori
marker
includ
interleukin
il
myeloperoxidas
exacerb
associ
viru
like
lead
hospit
viral
infect
identifi
ed
patient
copd
exacerb
requir
intub
mechan
ventil
interferong
induc
protein
chemokin
secret
bronchial
epitheli
cell
monocyt
lymphocyt
neutrophil
respons
interferong
tumor
necrosi
factora
shown
elev
hrv
infect
hrv
infect
replic
bronchial
epitheli
cell
activ
replic
hrv
trigger
product
cytokin
chemokin
includ
date
specifi
c
biomark
determin
causat
copd
exacerb
heterogen
event
although
airway
blood
marker
increas
baselin
exacerb
specifi
c
system
biomark
use
marker
airway
hrv
posit
copd
therefor
object
studi
assess
use
serum
marker
airway
hrv
posit
exacerb
assess
relationship
serum
airway
hrv
load
also
investig
differ
serum
level
patient
copd
baselin
control
subject
posit
neg
hrv
one
hundr
thirtysix
patient
studi
april
may
seventi
smoke
nonsmok
control
subject
similar
age
without
copd
recruit
primari
care
practic
recruit
monitor
patient
london
copd
studi
previous
describ
detail
avail
onlin
supplement
studi
approv
royal
free
hospit
research
ethic
committe
patient
gave
written
inform
consent
initi
visit
daili
respiratori
symptom
smoke
histori
drug
histori
comorbid
record
patient
control
height
weight
measur
along
baselin
lung
function
use
volumetr
storag
spiromet
vitalograph
maid
moreton
buckingham
england
blood
collect
creactiv
protein
crp
assay
patient
control
subject
nasopharyng
swab
np
taken
possibl
spontan
produc
sputum
collect
avail
patient
copd
patient
copd
least
day
postexacerb
day
preexacerb
onset
sampl
patient
shown
figur
copd
control
median
pgml
iqr
pgml
respect
p
regress
analysi
account
age
smoke
statu
sex
diseas
copd
control
still
effect
diseas
statu
p
crp
measur
patient
copd
control
measur
patient
control
crp
higher
patient
copd
control
median
mgl
mgl
respect
p
differ
serum
median
pgml
pgml
respect
p
higher
correl
increas
age
patient
copd
control
rho
p
rho
p
respect
serum
correl
smoke
packyear
patient
copd
rho
p
serum
correl
increas
diseas
sever
lower
fev
predict
patient
copd
rho
p
place
swab
immedi
place
eppendorf
contain
ml
phosphatebuff
salin
store
rna
extract
sputum
sampl
examin
within
h
collect
sampl
separ
contamin
saliva
process
use
previous
publish
method
rna
extract
revers
transcript
rna
extract
np
use
high
pure
viral
rna
kit
roch
burgess
hill
england
accord
manufactur
instruct
cdna
prepar
use
highcapac
cdna
revers
transcript
kit
appli
biosystem
warrington
cheshir
england
follow
manufactur
instruct
pcr
realtim
pcr
perform
use
abi
prism
real
time
pcr
system
appli
biosystem
sampl
initi
run
singl
posit
sampl
repeat
duplic
data
pool
two
run
vari
sampl
rerun
triplic
detail
control
standard
use
found
onlin
supplement
data
analyz
use
spss
version
stata
stata
corpor
colleg
station
tx
kolmogorovsmirnov
test
normal
appli
normal
distribut
data
express
mean
sd
skew
data
express
median
interquartil
rang
iqr
pearson
correl
use
assess
parametr
data
spearman
rank
use
assess
nonparametr
correl
wilcoxon
mann
whitney
u
test
use
pair
unpair
nonparametr
test
respect
regress
analysi
valu
log
transform
p
taken
signifi
cant
statist
analysi
use
confi
rming
presenc
hrv
exacerb
investig
receiv
oper
characterist
roc
curv
analysi
result
express
area
curv
auc
ci
accept
standard
auc
one
hundr
thirti
six
patient
copd
studi
men
women
baselin
characterist
cohort
report
tabl
patient
mean
fev
l
predict
seventi
control
subject
studi
men
women
baselin
characterist
report
tabl
control
subject
mean
fev
l
predict
signifi
cant
differ
age
smoke
histori
oxygen
satur
control
subject
patient
copd
p
bmi
p
eightyseven
patient
copd
control
subject
neg
hrv
sampl
np
andor
sputum
baselin
visit
serum
measur
figur
show
serum
level
higher
patient
viral
load
exacerb
serum
level
correl
sputum
viral
load
fig
rho
p
viral
load
measur
np
rho
p
np
viral
load
correl
sputum
viral
load
rho
p
hrv
load
signifi
cantli
higher
sputum
np
median
pfuml
pfuml
p
relationship
crp
viral
load
sputum
fig
b
c
np
crp
rho
p
fortynin
patient
copd
control
subject
sampl
stabl
state
found
hrv
posit
low
level
use
sensit
cutoff
pfuml
posit
asymptomat
time
presenc
hrv
increas
serum
level
either
patient
copd
control
subject
median
patient
test
hrv
neg
report
coryz
symptom
rho
p
rho
p
rho
p
furthermor
crp
correl
rho
p
rho
p
respect
cold
symptom
exacerb
exacerb
patient
report
coryz
symptom
wherea
two
patient
data
avail
figur
show
patient
report
patient
higher
level
hrv
neg
report
coryz
symptom
median
pgml
pgml
p
fig
b
appli
data
clinic
practic
set
cutoff
hrv
load
associ
copd
exacerb
thirteen
patient
posit
hrv
sputum
baselin
exacerb
figur
show
sputum
hrv
load
signifi
cantli
higher
exacerb
hrvposit
baselin
median
pfuml
exacerb
pfuml
baselin
p
signifi
cantli
higher
hrvposit
exacerb
examin
role
marker
exacerb
recoveri
increas
interest
postexacerb
period
morbid
still
signifi
cant
studi
neither
serum
crp
serum
correl
hrv
load
level
remain
low
independ
high
viral
load
thu
indic
poor
marker
hrvposit
copd
exacerb
previou
studi
shown
exacerb
asthma
neither
serum
signifi
cantli
differ
viral
nonvir
exacerb
data
confi
rmed
fi
nding
copd
respons
experiment
infect
hrv
copd
nasal
lavag
increas
significantli
chang
sputum
baselin
exacerb
greater
hrv
present
absolut
sputum
level
higher
exacerb
viru
detect
nasal
lavag
thu
although
airway
marker
may
potenti
indic
presenc
hrv
exacerb
sputum
readili
avail
patient
serum
appear
novel
appropri
marker
import
presenc
hrv
sputum
low
concentr
stabl
copd
fulli
understood
associ
heighten
infl
ammatori
respons
measur
serum
follow
extens
discuss
group
chose
sensit
cutoff
pfuml
hrv
detect
exploratori
analysi
none
neg
water
control
posit
level
howev
cross
reactiv
rsv
standard
curv
extrapol
reach
point
low
level
detect
baselin
predominantli
np
sampl
use
exacerb
roc
analysi
sensit
cutoff
may
account
greater
proport
asymptomat
hrv
posit
found
baselin
control
popul
patient
base
differ
hrv
load
baselin
exacerb
fig
use
sputum
sampl
hrv
load
np
correl
sputum
load
chose
log
hrv
load
valu
correspond
pfuml
higher
upper
limit
iqr
baselin
sampl
less
exacerb
sampl
would
suggest
presenc
hrv
load
pfuml
exacerb
indic
hrv
caus
exacerb
anyth
level
although
hrv
present
caus
symptom
exacerb
trigger
much
infl
ammatori
respons
base
roc
analysi
cutoff
hrv
use
sputum
sampl
baselin
exacerb
hrv
posit
neg
presenc
cold
symptom
day
visit
auc
alon
ci
use
presenc
coryz
symptom
alon
auc
use
combin
coryz
symptom
auc
fig
thu
measur
blood
presenc
coryz
symptom
exacerb
likelihood
hrv
infect
determin
appli
cutoff
blood
pgml
presenc
cold
symptom
would
specifi
c
sensit
hrv
exacerb
shown
fi
rst
time
serum
increas
baselin
exacerb
copd
specifi
calli
exacerb
posit
hrv
serum
previous
shown
increas
virustrigg
acut
asthma
exacerb
shown
copd
exacerb
sputum
hrv
load
determin
quantit
rtpcr
correl
level
blood
although
hrv
infect
individu
mild
selflimit
patient
copd
viral
infect
trigger
exacerb
increas
sever
exacerb
lengthen
recoveri
time
increas
likelihood
hospit
thu
serum
may
use
biomark
identifi
patient
earli
intervent
either
standard
exacerb
therapi
futur
novel
antivir
agent
studi
show
sputum
hrv
load
correl
serum
exacerb
thu
may
use
detect
presenc
hrv
monitor
hrv
exacerb
length
respons
treatment
current
good
marker
exacerb
sever
hrv
caus
sever
exacerb
virusneg
exacerb
eas
sampl
blood
make
serum
practic
marker
sputum
marker
work
requir
copd
compar
studi
studi
use
differ
primer
probe
design
detect
fewer
strain
hrv
factor
lead
lower
detect
rate
hrv
pcr
design
detect
mani
differ
strain
hrv
possibl
sampl
baselin
spring
autumn
hrv
preval
relev
low
level
hrv
copd
clear
felt
import
investig
may
play
role
exacerb
suscept
virus
circul
year
round
like
patient
copd
acquir
viru
frequent
possibl
low
level
howev
strain
hrv
demonstr
pathogen
increasingli
sensit
method
viral
detect
avail
use
viral
load
determin
signifi
canc
presenc
viru
increasingli
common
use
data
suggest
cutoff
viral
load
signifi
cant
exacerb
ie
like
caus
exacerb
symptom
integr
defi
nition
copd
exacerb
coryz
symptom
put
marker
viru
posit
reason
combin
presenc
coryz
symptom
predictor
hrv
posit
current
data
roc
analysi
present
indic
serum
pgml
presenc
cold
symptom
indic
hrv
exacerb
test
whether
increas
exacerb
presenc
respiratori
virus
tissu
cultur
shown
increas
presenc
infl
uenza
viru
mice
level
increas
respons
rsv
confi
rmed
vivo
although
possibl
virus
test
may
infl
uenc
fi
nd
increas
presenc
coryz
symptom
marker
viral
infect
hrv
detect
cold
ill
usual
caus
respiratori
virus
found
coldassoci
exacerb
neg
hrv
increas
serum
level
strengthen
case
biomark
hrv
infect
airway
exacerb
shown
patient
copd
higher
serum
level
stabl
state
control
may
also
play
role
infl
ammatori
process
copd
express
receptor
higher
airway
smoker
copd
present
higher
level
induc
sputum
patient
copd
compar
control
fi
nding
correl
neg
packyear
smoke
indic
local
upregul
airway
spill
system
circul
studi
focus
role
marker
hrv
infect
defi
ned
role
bacteria
although
known
marker
bacteri
infect
previou
studi
concentr
hrv
possibl
virus
may
also
affect
level
deserv
studi
interest
np
load
relat
serum
know
cold
alway
lead
exacerb
upper
airway
diffi
cult
sampl
conclus
shown
serum
use
novel
biomark
hrv
infect
exacerb
copd
serum
higher
baselin
patient
copd
control
increas
age
measur
serum
may
enabl
ration
therapi
copd
exacerb
reduc
morbid
disabl
diseas
author
contribut
dr
quint
contribut
concept
design
studi
acquisit
sampl
elisa
process
data
analysi
interpret
write
fi
rst
draft
manuscript
edit
revis
manuscript
dr
donaldson
contribut
concept
design
studi
data
analysi
interpret
edit
revis
manuscript
dr
goldr
contribut
acquisit
sampl
edit
revis
manuscript
dr
baghairavari
contribut
acquisit
sampl
edit
revis
manuscript
dr
hurst
contribut
concept
design
studi
interpret
data
edit
revis
manuscript
dr
wedzicha
contribut
concept
design
studi
interpret
data
edit
revis
manuscript
financialnonfi
nancial
disclosur
author
report
chest
potenti
confl
ict
interest
exist
companiesorgan
whose
product
servic
may
discuss
articl
contribut
thank
william
zermanski
highgat
group
primari
care
practic
help
recruit
control
